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Improvement of Postnatal Neovascularization by Human
Embryonic Stem Cell–Derived Endothelial-Like Cell
Transplantation in a Mouse Model of Hindlimb Ischemia
Seung-Woo Cho, PhD*; Sung-Hwan Moon, MS*; Soo-Hong Lee, PhD*; Sun-Woong Kang, MS;
Jumi Kim, MS; Jae Min Lim, MS; Hyo-Soo Kim, MD, PhD;
Byung-Soo Kim, PhD†; Hyung-Min Chung, PhD†
Background—We established an efficient preparation method to obtain endothelial-like cells (ECs) from human
embryonic stem cells (hESCs) and tested whether these hESC-ECs would show therapeutic potential for treatment of
hindlimb ischemia.
Methods and Results—ECs differentiated from hESCs were obtained by mechanical isolation and cell sorting for von
Willebrand factor. The isolated hESC-ECs maintained endothelial cell–specific characteristics such as endothelial marker
expression and capillary formation. One day after surgical induction of hindlimb ischemia in athymic mice, hESC-ECs were
injected intramuscularly into ischemic limbs. Four weeks after treatment, hESC-EC treatment significantly increased limb
salvage (36%) compared with treatment with medium (0%). In addition, laser Doppler imaging showed that the ratio of blood
perfusion (ischemic to normal limb) was increased significantly (P0.01) by hESC-EC treatment (0.5110.167) compared
with medium injection (0.0730.061). Capillary and arteriole densities were 658190/mm2 and 3011/mm2 in the hESC-EC
group, respectively, whereas those in the medium group were 392118/mm2 and 168/mm2, respectively (P0.01).
Reverse-transcription polymerase chain reaction with human-specific primers revealed mRNA expression of human
endothelial markers and human angiogenic factors in ischemic mouse tissues. The transplanted hESC-ECs were localized as
capillaries near muscle tissues in ischemic regions or incorporated in the vessels between muscle tissues, as confirmed by
human nuclear antigen staining with platelet/endothelial cell adhesion molecule or von Willebrand factor.
Conclusions—This study demonstrates that hESC-EC transplantation improves blood perfusion and limb salvage by
facilitating postnatal neovascularization in a mouse model of hindlimb ischemia. Thus, hESC-ECs might be useful as
an alternative cell source for angiogenic therapy. (Circulation. 2007;116:2409-2419.)
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Recently, angiogenic stem cell transplantation has beenused to induce neovascularization in animal models of
limb and myocardial ischemia. Transplantation of endothelial
progenitor cells (EPCs) isolated from peripheral blood,1 bone
marrow,2 or cord blood3 induces collateral blood vessel
development in ischemic limbs and myocardium. In an
animal model of severe limb ischemia, therapy with adipose
tissue–derived stromal cells was found to enhance neovascu-
larization through a paracrine effect by angiogenic factor
secretion.4 In spite of the angiogenic potential of these adult
stem cells for treatment of ischemic diseases, these cell
sources have limitations for therapeutic angiogenesis. Isola-
tion of EPCs from peripheral blood or bone marrow requires
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the harvesting of a large amount of autologous blood to
obtain a sufficient number of EPCs.5 This may cause com-
plications in some patients with severe cardiovascular disease
such as myocardial infarction or atherosclerosis. Although
adult stem cells derived from cord blood and adipose tissue
are favorable with regard to obtaining the number of cells
required for transplantation, few transplanted stem cells have
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been found to differentiate into endothelial cells (ECs) and
incorporate into vascular structures in ischemic sites.6,7
Recently, embryonic stem cells (ESCs) have been high-
lighted as an alternative cell source for therapeutic angiogen-
esis. ESCs are known to exhibit unlimited proliferation and
pluripotency, and they are promising resources for regenera-
tive medicine, which requires large numbers of a particular
cell type, including ECs.8 During the early stages of ESC
development, vasculogenesis takes place through a multistep
process in which EC precursors differentiate, expand, and
coalesce to form a network of primitive tubules. There have
been several reports indicating that ESCs can spontaneously
differentiate into ECs in vitro or in vivo.9,10 Furthermore, ECs
can be obtained from Flk-1– or Sca-1–positive cell fractions
in ESCs in vitro.11,12 ESC-derived ECs express EC–specific
genes and proteins and have been found to form mature
vascular, capillary-like structures in a 2D and 3D in vitro
culture, which indicates that they have functional EC-specific
characteristics.13,14 Thus, ESCs could be used as a source of
ECs for the treatment of ischemia or for cardiovascular tissue
engineering. Indeed, a previous study reported that transplan-
tation of mouse ESC–derived ECs accelerated reendotheli-
alization of injured arteries and reduced neointimal hyperpla-
sia.12 However, no study has yet reported on the therapeutic
potential of human ESC-ECs (hESC-ECs) for the treatment
of ischemic diseases.
In the present study, we first investigated whether a large
population of pure ECs could be obtained from human ESCs
(hESCs). We found that platelet/endothelial cell adhesion
molecule (PECAM)–positive cells were located mainly at the
centers of embryoid bodies (EBs) during differentiation of
hESCs. After attachment of EBs on culture dishes, PECAM-
positive cells in the center region of the attached EBs were
collected efficiently from the outgrowth of EB cells by
mechanical isolation. This technique allowed us to acquire a
large enough number of cells to be transplanted into ischemic
hindlimbs. We subsequently tested the hypothesis that hESCs
could show therapeutic potential to treat ischemic disease.
Endothelial-like cells isolated from hESCs were expanded in
vitro and transplanted into limb muscles of a mouse hindlimb
ischemia model. The therapeutic efficacy of hESC-EC trans-
plantation was evaluated by measurement of blood perfusion
in ischemic limbs. The angiogenic efficacy of hESC-EC
therapy was examined by immunohistochemical analyses,
reverse-transcription polymerase chain reaction (RT-PCR)
assay, and microvessel density determination in the ischemic
tissues.
Methods
An expanded Methods section is provided in the online-only Data
Supplement.
hESCs Culture and Endothelial Differentiation
The undifferentiated hESCs (cell line CHA3-hESC) was cultured as
described previously.15 Every 5 to 6 days, hESCs were detached with
dissecting pipettes and transferred to dishes with mitomycin
C–treated STO feeder cells (ATCC, Manassas, Va), as described
previously.16 For EB formation, hESCs were cultured in suspension
in basic fibroblast growth factor–free hESC culture medium for 9
days. The resulting EBs were attached to dishes and cultured for 7 to
9 days in DMEM (Gibco, Gaithersburg, Md) supplemented with
10% fetal bovine serum (HyClone, Logan, Utah). The center regions
of attached EBs were isolated mechanically with dissecting pipettes
from the surrounding outgrowth cells, and the isolated cells were
cultured in defined medium for EC culture (EGM-2; Cambrex,
Walkersville, Md). To isolate von Willebrand factor (vWF)–positive
cells from cells in the center region, cell sorting with mouse
anti-human monoclonal vWF antibodies (Chemicon, Temecula,
Calif) was performed with a FACS Vantage flow cytometer (BD
Bioscience, San Jose, Calif). The sorted cells were cultured with
EGM-2 up to 5 passages to obtain sufficient cells for in vivo
injection (3.5107 cells).
Mouse Limb Ischemia
Female athymic mice at 4 weeks of age (body weight 15 to 18 g;
Jungang Laboratory Animal, Seoul, Korea) were anesthetized with
xylazine (20 mg/kg) and ketamine (100 mg/kg). The femoral artery
and its branches were ligated through a skin incision with 5-0 silk
(Ethicon, Somerville, NJ). The external iliac artery and all of the
above arteries were then ligated. The femoral artery was excised
from its proximal origin as a branch of the external iliac artery to the
distal point where it bifurcates into the saphenous and popliteal
arteries.17 All animals received humane care in compliance with the
“Guide for the Care and Use of Laboratory Animals” published by
the National Institutes of Health (National Institutes of Health
publication No. 85-23, revised 1996).
Treatments of Limb Ischemia
One day after arterial dissection, athymic mice were randomly
assigned to 1 of 2 experimental groups. The control group (n10)
was injected with medium. hESC-ECs (3.0106 cells per mouse)
were suspended in 200 L of EGM-2 (hESC-EC group, n11) and
injected intramuscularly into 4 sites of the gracilis muscle in the
medial thigh with 29-gauge tuberculin syringes.
Laser Doppler Imaging Analysis
Laser Doppler imaging analysis was performed as described previ-
ously.18 A laser Doppler perfusion imager (Moor Instruments,
Devon, United Kingdom) was used for serial noninvasive physio-
logical evaluation of neovascularization. Mice were monitored by
serial scanning of surface blood flow of hind limbs on days 0, 14, and
28 after treatment. The digital color-coded images were analyzed to
quantify the blood flow in the region from the knee joint to the toe,
and mean values of perfusion were calculated.
Statistical Analysis
Quantitative data are expressed as meanSD. Statistical analysis
was performed with the unpaired Student t test with InStat software
(InStat 3.0, GraphPad Software Inc, San Diego, Calif). A value of
P0.05 was considered statistically significant.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Efficient Isolation and Culture of hESC-ECs
Figure 1 shows the overall strategy to efficiently acquire ECs
from hESCs. First, hESCs were prepared on feeder cells by
conventional hESC culture techniques (Figure 1A). Second,
EBs were spontaneously formed by suspension culture after
removal of the feeder cells. Surprisingly, immunocytochem-
ical staining for PECAM of differentiated EBs showed that a
majority of PECAM-positive cells were localized at the
centers of EBs (Figure 1B). In the hESC line (CHA3-hESC,
online-only Data Supplement Figure I) used in the present
study, a considerable amount of PECAM expression was
observed in the EBs after 9 days of culture (online-only Data
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Supplement Figure IIB and IIC). In addition, the EBs main-
tained morphological similarity for up to 9 days after differ-
entiation (online-only Data Supplement Figure IIA). Third,
differentiated EBs were attached on culture dishes, which
allowed the outer cells of EBs to spread more rapidly toward
the outer edges than cells in the centers of the EBs. Attached
EBs had 2 different regions in terms of PECAM expression.
PECAM was mainly found at the center regions of attached
EBs (Figure 1C). Therefore, we were easily able to acquire a
large population of PECAM-positive cells by isolating the
center regions of attached EBs from surrounding cells
through mechanical isolation (Figure 1D). Online-only Data
Supplement Figure III shows the proportions of vWF- and
PECAM-positive cells in the EBs at each isolation stage.
When the isolated cells were plated again onto gelatin-coated
dishes, they exhibited vascular-like structures, which con-
firmed the existence of a large population of ECs (Figure 1E).
Subsequently, cultured isolated cells were sorted with vWF
antibodies by fluorescent-activated cell sorter (FACS) anal-
ysis (Figure 1F). The sorted cells were expanded (Figure 1G)
and injected into the hindlimb-ischemia mouse model for an
in vivo function test (Figure 1H).
Characterization of hESC-ECs
Expressions of an undifferentiated marker gene (Oct-4) and
endothelial-specific genes (PECAM, VE-cadherin, Tie-2, and
Flk-1) were analyzed at different stages of hESC differenti-
ation with RT-PCR (Figure 2A). In accordance with progress
in the isolation process (hESC differentiation), Oct-4 expres-
sion decreased, whereas expression of all endothelial markers
increased, which indicated that ECs were isolated effectively.
FACS sorting for vWF revealed that the vWF-positive cell
population was 41.81% of the total cell population in me-
chanically isolated cells (Figure 2B). The sorted cells showed
a cobblestone shape, a morphology typical of ECs (Figure
2C). RT-PCR analysis of hESC-ECs used for transplantation
showed expression of multiple endothelial markers (PECAM,
VE-cadherin, Tie-2, Flk-1, and vWF) in hESC-ECs (Figure
2D). The hESC-ECs were stained positively for various EC
markers (vWF, PECAM, and VE-cadherin; Figure 2E). PECAM
was expressed at the junction of cells, whereas vWF was
largely expressed in the cytoplasm (Figure 2E). FACS data
for vWF in hESC-ECs used for in vivo injection indicated
that a majority of hESC-ECs (91.35%) were positive for vWF
(Figure 2F). The expression of other EC markers (Tie-2,
Flt-1, and KDR) was observed in cells over 60% of the total
hESC-EC population (Figure 2F).
hESC-ECs were examined further in view of EC-specific
functions. When the sorted cells were incubated with 1,
1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine (DiI)–
labeled acetylated low-density lipoprotein (LDL), its fluores-
cence (red color) was observed in the cytoplasm of cells,
showing the uptake of ac-LDL. The overlapped fluorescent
image of acetylated LDL and DAPI confirmed that acetylated
Figure 1. Overall strategy to isolate and culture hESC-ECs and transplant them into a hindlimb ischemia mouse model.
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LDL was localized in the cytoplasm (Figure 3A). Addition-
ally, the sorted cells on Matrigel spontaneously sprouted and
branched, which resulted in well-defined networks of capil-
lary structures (Figure 3B). The formation of capillary-like
structures was observed within 12 hours after plating. The
cells in capillary structures distinctly expressed endothelial-
specific PECAM, vWF, and VE-cadherin (Figure 3C through
3E). Lumen structures were observed in vascular networks
formed on Matrigel and maintained their stability in Matrigel
during in vitro culture for 5 to 7 days (Figure 3D and 3E).
Improvement of Ischemic Limb Salvage by
hESC-EC Transplantation
The angiogenic potential of hESC-ECs was evaluated in an
athymic mouse model of hindlimb ischemia. At 4 weeks after
the injection treatment, the control group (medium injection)
showed extensive necrosis of the ischemic hindlimb, which
resulted in limb loss by autoamputation (Figure 4A). The
intramuscular transplantation of hESC-ECs significantly re-
duced the rate of limb loss compared with injection with
medium alone. All mice receiving medium injection under-
went limb loss (90%, 9 of 10) or severe limb necrosis (10%,
1 of 10), with no cases of limb salvage. On the other hand,
most of the mice that received hESC-EC transplantation
exhibited limb salvage (36.4%, 4 of 11) or had only mild limb
necrosis (36.4%, 4 of 11), although some of these mice lost
their limbs (27.2%, 3 of 11; Figure 4B).
Inhibition of Muscle Degeneration and Fibrosis in
Ischemic Limbs by hESC-EC Transplantation
Histological examinations of the ischemic limbs retrieved at
4 weeks after the injection treatment revealed that hESC-EC
transplantation protected limb muscles against necrotic dam-
age caused by ischemia. Hematoxylin and eosin staining of
the control group (medium injection) showed massive muscle
degeneration in the ischemic regions (Figure 4C). In contrast,
muscles in the ischemic limbs of mice in the hESC-EC
transplantation group were protected after cell transplantation
(Figure 4C). Masson’s trichrome staining showed that fibro-
sis was markedly attenuated after local transplantation of
hESC-ECs into the ischemic regions (Figure 4C).
Improvement of Blood Perfusion in Ischemic
Limbs by hESC-EC Transplantation
Laser Doppler perfusion imaging analysis revealed that blood
perfusion in ischemic limbs was significantly improved in the
hESC-EC transplantation group compared with the medium-
Figure 2. hESC-EC isolation and characterization. A, RT-PCR for examination of EC-specific marker expression in EBs during hESC
differentiation. B, FACS analysis for vWF of cells isolated mechanically from EBs. C, Morphology of hESC-ECs sorted in Figure 2B.
Sorted cells were expanded up to 5 passages for in vivo injection. D, RT-PCR for various endothelial markers of hESC-ECs. Human
umbilical vein ECs (HUVECs) and undifferentiated hESCs were used as a positive and negative control, respectively. E, Immunocyto-
chemical staining of hESC-ECs for multiple EC markers. Cultured hESC-ECs showed cobblestone morphology (left), a typical EC mor-
phology, and were stained positively with endothelial markers (vWF/PECAM [middle] and VE-cadherin [right]). F, FACS analyses of
hESC-ECs used for in vivo injection. hESC-ECs continued to express EC markers highly during the culture.
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injection group (Figure 5A). At 2 weeks after treatment, the
relative ratios of blood flow (ischemic to normal limb) were
0.2350.085 in the hESC-EC transplantation group (n8)
and 0.0510.017 in the medium-injection group (n7),
respectively (P0.01; Figure 5B). Intramuscular transplan-
tation of hESC-ECs significantly improved the relative
ratio of blood perfusion (hESC-EC transplantation group
0.5110.167, n11, versus medium-injection group
0.0730.061, n10; P0.01) by 4 weeks after treatment
(Figure 5B). Smaller doses of cells (3.0104 and 3.0105
cells per mouse) also yielded improvements in blood perfu-
sion (3.0104 group [n3] 0.3590.036, 3.0105 group
[n4] 0.4070.032; P0.01 versus medium group
0.1160.041 [n5]) in ischemic limbs at 4 weeks after
treatment (online-only Data Supplement Figure IVA and
IVC). However, mice treated with 3.0104 cells underwent
more severe foot necrosis at 4 weeks than mice treated with
3.0105 cells (online-only Data Supplement Figure IVB).
Injection of cells negative for vWF (non-EC component of
the EBs) after sorting for vWF did not yield improvements in
blood perfusion (0.1960.074, n3) in ischemic limbs
compared with the medium-injection group (0.1160.041,
n5; P0.05) at 4 weeks after treatment (online-only Data
Supplement Figure IVA and IVC).
Enhancement of Neovascularization by
hESC-EC Transplantation
Transplanted hESC-ECs enhanced angiogenesis, arteriogenesis,
and angiogenic factor expression in ischemic limb tissues. With
the use of immunohistochemical staining for vWF (Figure 6A)
and quantification of capillary density (Figure 6D), it was
revealed that hESC-EC transplantation significantly enhanced
capillary formation (658190/mm2) compared with medium
injection (392118/mm2; P0.01). Immunohistochemical
staining for PECAM (Figure 6C) confirmed this enhanced
capillary formation by hESC-EC transplantation. Immunohisto-
chemical staining for smooth muscle -actin (Figure 6B) and
quantification of arteriole density (Figure 6E) revealed that
arteriole formation was significantly enhanced (P0.01) by
hESC-EC transplantation (3011/mm2) compared with medium
injection (168/mm2). RT-PCR analysis with human-specific
primers for multiple endothelial markers showed that the expres-
sion of human endothelial marker mRNA was detected in
ischemic limb tissues only in the hESC-EC transplantation
group (Figure 6F). Furthermore, the mRNA expression of
human EC markers (hESC-EC group in Figure 6F) was compa-
rable to that of mouse EC markers (hESC-EC group in Figure
6G), which demonstrates that a therapeutic contribution of
hESC-ECs to neovascularization was significantly induced in
ischemic tissues.
Figure 3. Endothelial-specific functional characterization of hESC-ECs. A, Acetylated LDL uptake by hESC-ECs. Red in cytoplasm rep-
resents DiI-labeled acetylated LDL. Human umbilical vein ECs (HUVEC) and STO fibroblasts were used as a positive and negative con-
trol, respectively. B, Vascular tubelike networks formed by hESC-ECs on Matrigel at 5 days after plating. C through E, Immunocyto-
chemical staining of the vascular networks formed on Matrigel for PECAM (red), vWF or VE-cadherin (green), and DAPI (blue). Stable
lumen structures were observed in the vascular networks during in vitro culture of 5 to 7 days. VE-cad indicates VE-cadherin.
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Human angiogenic factor expression by hESC-EC transplan-
tation was also observed in mouse ischemic tissues. Immuno-
histochemical staining for vascular endothelial growth factor and
basic fibroblast growth factor showed significant expression of
these human factors in the hESC-EC injection group (Figure 7A
and 7B). Moreover, RT-PCR analysis with human-specific
primers proved that transplanted hESC-ECs induced the expres-
sion of human angiogenic growth factor mRNA in ischemic
regions. Human vascular endothelial growth factor, basic fibro-
blast growth factor, and angiopoietin-1 mRNA were distinctly
expressed in the ischemic limbs that received hESC-EC trans-
plantation (Figure 7C). The mRNA expression of these human
angiogenic factors was not observed in the ischemic limbs that
received medium injection (Figure 7C).
Engraftment of Transplanted hESC-ECs Into
Vascular Structures in Ischemic Limbs
RT-PCR for human -actin and fluorescence in situ hybrid-
ization staining revealed the presence of human cells in
ischemic tissues after transplantation. The expression of
human -actin mRNA was detected in hESC-EC–trans-
planted limb tissues but not in medium-injected limb tissues
(Figure 8A). Fluorescence in situ hybridization staining
showed human cells with Y chromosomes (arrows) in the
ischemic regions (Figure 8B). PECAM immunostaining with
human-specific antibodies showed that the human PECAM-
positive vessel contained red blood cells in its lumen (Figure
8C, arrow), which indicates that the neovessels induced by
hESC-EC transplantation were apparently functional and
indeed contributed to the blood perfusion. Double-immunofluo-
rescent staining for human nuclear antigen and PECAM
(Figure 8D) showed that human nuclear antigen– and
PECAM-positive cells (transplanted hESC-ECs, arrows)
were present in the ischemic regions. The formation of
capillary networks between PECAM-positive human cells
(transplanted hESC-ECs, arrows) and PECAM-positive
mouse cells (recruited mouse ECs, arrowheads) was also
Figure 4. Improvement of ischemic limb salvage by hESC-EC transplantation. A, Representative photographs of medium-treated (left)
and hESC-EC–treated (right) ischemic hindlimbs on days 0, 14, and 28 after treatment. B, Physiological status of ischemic limbs 4
weeks after medium injection or hESC-EC transplantation. Intramuscular transplantation of hESC-ECs improved the salvage of ische-
mic limbs compared with medium injection. C, Histological analyses of normal limbs and ischemic limbs retrieved 4 weeks after treat-
ment. Staining with hematoxylin and eosin (H&E; original magnification 400) showed massive muscle degeneration in the ischemic
regions of control limbs. Infiltration of numerous granulocytes and neutrophils, indicative of tissue inflammation after ischemia, was
observed in the ischemic regions. In contrast, muscles in the ischemic limbs of the hESC-EC transplantation group were protected
after cell transplantation. Masson’s trichrome staining (original magnification 400) showed that fibrosis was markedly attenuated after
local transplantation of hESC-ECs into the ischemic regions.
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observed in the ischemic muscles (Figure 8D). The trans-
planted hESC-ECs were found at capillaries near muscle
tissues in ischemic regions (Figure 8D) or incorporated in the
vessels between muscle tissues (Figure 8D and 8E). Human
nuclear antigen staining with PECAM (Figure 8D) or vWF
(Figure 8E) confirmed the presence of hybrid blood vessels
composed of transplanted hESC-ECs (arrows) and mouse
ECs (arrowheads). The density of hESC-ECs (human nuclear
antigen– and PECAM-positive cells) that existed in ischemic
tissues was 161137 cells/mm2. The densities of mouse
EC–derived vessels and hESC-EC–incorporated hybrid ves-
sels were 10265/mm2 and 2436/mm2, respectively
(P0.01; Figure 8F). Blood vessels composed of only trans-
planted human cells were not detected (Figure 8F). These
results suggest that transplanted hESC-ECs survived after
transplantation, were engrafted into mouse tissue, and subse-
quently induced vascular networks in the ischemic muscles.
Discussion
ESCs could be an alternative cell source for use in therapeutic
angiogenesis to treat ischemic diseases. First, ESCs could
provide functional ECs in unlimited amounts that would be
available for clinical application. It has been reported that the
number of EPCs in adult stem cell sources, such as bone
marrow or peripheral blood, is limited.4 In addition, adult
stem cells usually have a limited proliferative capacity, and
thus, expansion of sufficient EC populations from these adult
stem cells for transplantation remains a major task.19 In
contrast, ESCs have an extended self-renewal activity and can
be expanded without limit.20 Second, ESCs may show low
immunogenicity in vivo, although this is rather controversial
at this point. It has been reported that ESCs express few
immune-related cell-surface antigens21; thus, ESCs and their
derivatives may be less susceptible to immune rejection than
adult cells.22 Indeed, several studies report the immune
tolerance of transplanted mouse ESCs in rat23 and sheep24
infarcted myocardium. However, a recent study demonstrated
that mouse ESCs were immunologically rejected several
weeks after transplantation into mouse ischemic myocardium,
which indicates the lack of immune tolerance of ESC deriv-
atives even in allogeneic transplantation.25 The immune
benefit of ESC therapy requires verification by immune-
competent animal study.
hESC-ECs could also potentially be used for cell therapy to
treat ischemic tissues or for vascular tissue engineering.
Unfortunately, in spite of these advantages of hESC-ECs
compared with adult stem cells, no studies have investigated
the use of hESC-ECs to improve therapeutic angiogenesis for
clinical application, presumably because it is difficult to
produce hESC-ECs on a large scale and with high purity.
Many recent studies have used EBs to acquire ECs differen-
tiated from hESCs, because EBs can be formed simply from
hESCs and can be handled easily. However, investigators
failed to produce the number of hESC-ECs needed for in vivo
study. For example, Levenberg et al9 isolated an 2% yield
of ECs by sorting PECAM-positive cells in EBs.
In the present study, we sought to acquire a high yield of
hESC-ECs from a majority of PECAM-positive cells located
at the center of EBs formed after suspension culture. Surpris-
ingly, most of the PECAM-positive cells remained in the
center of the EBs even after attachment to culture dishes,
which resulted in 2 regions of EC populations. We also
verified a similar distribution of PECAM-positive cells in the
center regions of EBs from another hESC line (H9 cell line;
data not shown) and efficiently isolated the cells in the center
regions, which demonstrates that PECAM-positive cells pref-
Figure 5. Improvement in blood flow in ischemic hindlimbs after hESC-EC transplantation. A, Serial analysis of laser Doppler perfusion
imaging at 0, 14, and 28 days after treatment. A greater increase in limb blood perfusion was observed in the ischemic limbs of mice
that received hESC-EC transplantation than in the medium-injection group. B, Blood perfusion ratio of ischemic limbs measured by
laser Doppler imaging at 0, 14, and 28 days after treatment. The ratio of ischemic to normal limb blood perfusion was significantly
improved in mice that received hESC-EC transplantation compared with the medium-injection group at 2 weeks (n7 for medium and
n8 for hESC-ECs; *P0.001) and 4 weeks (n10 for medium and n11 for hESC-ECs; *P0.001) after treatment.
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erentially develop at the center of EBs irrespective of hESC
line. After mechanical isolation of the PECAM-positive
cell-enriched fraction and sorting for vWF, a high yield of
pure ECs were obtained. FACS data for vWF of hESC-ECs
used for transplantation showed that a majority of hESC-ECs
(91.35%) were positive for vWF (Figure 2F), which was
comparable to a FACS result (92.06%) for vWF in human
umbilical vein endothelial cells, a homogeneous EC popula-
tion (online-only Data Supplement Figure IIIE), which indi-
cates the homogeneity of ECs used in the present study.
The present study is the first report demonstrating that
hESCs could be feasible as a novel cell source for therapeutic
angiogenesis in an animal model of severe ischemia. For
expansion of hESC-ECs with high purity, the present study
used an efficient EC culture method by combining mechan-
ical isolation and cell sorting with an endothelial-specific
marker. Local transplantation of hESC-ECs prepared by this
method improved perfusion blood flow in ischemic limbs
(Figure 5), which resulted in a lower rate of ischemic limb
loss (Figure 4B). The present study demonstrates that the
beneficial effect of hESC-ECs on ischemic tissues is attrib-
utable not only to their participation in the vascular structures
but also to their ability to produce angiogenic factors. Direct
incorporation of transplanted cells into vascular structures
could contribute to improvements in blood perfusion in
ischemic tissues through the induction of angiogenesis. The
present in vivo study showed that transplanted hESC-ECs
were incorporated into vascular networks in ischemic sites
(Figure 8D and 8E). The paracrine effects of factors secreted
by transplanted cells could be an additional part of their
contribution to the repair of ischemic tissues. RT-PCR
analysis revealed that human angiogenic growth factors
(vascular endothelial growth factor, basic fibroblast growth
factor, and angiopoietin-1) were expressed only in the ische-
mic limbs that received hESC-EC transplantation and not in
the limbs treated with medium (Figure 7C). This result may
indicate that additional human angiogenic factors secreted by
transplanted hESC-ECs further enhanced angiogenesis by
promoting a paracrine effect in ischemic tissues, which leads
to functional recovery of ischemic muscles. It has also been
reported that embryonic EPCs can secret a wide spectrum of
proteins related to cell survival and wound healing, as well as
angiogenic factors.26 Thus, hESC-ECs might prevent apopto-
sis in muscle tissue after ischemic lesion through the secre-
tion of antiapoptotic factors.
Figure 6. Enhancement of neovascularization in ischemic limb tissues at 4 weeks after hESC-EC transplantation. A through C, Immu-
nohistochemical staining with vWF (A), smooth muscle (SM) -actin (B), and PECAM (C). D and E, Quantification of capillary density (D)
and arteriole density (E) in ischemic regions of control group (medium injection) and hESC-EC–transplanted group. Capillary and arte-
riole formation were significantly enhanced (P0.01) by hESC-EC transplantation compared with medium injection. F and G, RT-PCR
analysis of ischemic limb tissues retrieved 4 weeks after treatment for multiple endothelial markers with (F) human- and (G) mouse-
specific primers. The same amounts of PCR products were loaded for human and mouse EC markers.
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The strategy for therapeutic ESC transplantation requires
more effective improvement for therapeutic angiogenesis. Al-
though hESC-EC transplantation improved blood perfusion in
ischemic limbs compared with control treatment (medium injec-
tion) in the present study, the therapeutic efficacy of hESC-EC
transplantation was rather low (4 of 11 cases of limb salvage).
Recent studies have shown that a combination of stem cell
transplantation and angiogenic or antiapoptotic factors or genes
synergistically enhanced neovascularization in ischemic tissues
compared with each therapy alone.27,28 Coadministration of
several growth factors enhanced ESC engraftment and host-
specific differentiation in hearts with myocardial infarction.29
Thus, combination therapy could be used to enhance the angio-
genic efficacy of hESC-EC transplantation. The present study
used cell sorting with a mature EC marker (vWF) to remove
undifferentiated ESCs or cells of different lineages. Although
teratoma formation was not observed in the present study,
animals receiving hESC-ECs were followed up for a relatively
short period of time (4 weeks), which may be insufficient to
allow for the formation of teratomas. Other techniques might be
introduced to completely eliminate the possibility of teratoma
formation. For example, antibiotic selection enabled by the
introduction of a fusion gene comprising an endothelial-specific
promoter and antibiotic resistance sequence into ESCs could aid
in EC isolation and in the prevention of teratoma formation.30
Cell transplantation with a matrix may enhance the efficacy of
cell therapy by facilitating optimal cell transfer and distribution
into ischemic sites. Indeed, ESC transplantation with injectable
hydrogel enhanced the efficacy of cell therapy in the treatment
of myocardial infarction.31 The number and type of hESC-ECs
used for transplantation should also be optimized to enhance
angiogenic efficacy.
In summary, we were able to acquire a high yield of ECs
through mechanical isolation of the center regions of attached
EBs that differentiated from hESCs and through subsequent
cell sorting for vWF. Compared with cells from whole EBs,
cells isolated from the center regions of EBs showed higher
PECAM expression and spontaneously formed well-defined
vascular structures. Thus, this isolation technique can be used
to produce a large population of ECs from hESCs. More
importantly, the present study provides evidence that trans-
planted hESC-ECs could act as an alternative source of cells
for therapeutic angiogenesis to treat peripheral ischemia.
hESC-EC therapy could also be used for treatment of other
ischemic diseases such as myocardial or cerebral ischemia.
However, because the present study is a preliminary work
with small immune-deficient animals, hESC-EC therapy
should be further tested in an immune-competent large-
animal model as a preclinical study to prove the therapeutic
potential and immune benefit of hESCs in the treatment of
severe ischemic diseases.
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Figure 7. Expression of human angio-
genic growth factors in ischemic limb
tissues by hESC-EC transplantation. A
and B, Immunohistochemical staining
for vascular endothelial growth factor
(VEGF; A) and basic fibroblast growth
factor (bFGF; B) with human-specific
antibodies. Significant expression of
these human factors was observed in
hESC-EC injection group. C, RT-PCR
analysis with human-specific primers
for angiogenic growth factors. Trans-
planted hESC-ECs induced the expres-
sion of human angiogenic growth fac-
tor mRNA in ischemic regions. Ang-1
indicates angiopoietin-1.
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CLINICAL PERSPECTIVE
Myocardial infarction, stroke, and coronary artery disease are devastating and life-threatening ischemic diseases. In this
study, we confirmed that human embryonic stem cells (hESCs) represent a new cell source for angiogenic therapy to treat
ischemic diseases. We differentiated hESCs through human embryoid body formation, and endothelial-like cells (ECs)
were obtained by mechanical isolation and cell sorting for von Willebrand factor. The isolated hESC-ECs maintained
endothelial cell–specific characteristics such as endothelial marker expression and capillary formation. hESC-ECs were
injected intramuscularly into ischemic limbs of mouse models, and 4 weeks after treatment, hESC-EC treatment
significantly increased limb salvage (36%) compared with treatment with medium (0%). In addition, the ratio of blood
perfusion (ischemic to normal limb) was increased significantly (P0.01) by hESC-EC treatment (0.5110.167) compared
with medium injection (0.0730.061). Capillary and arteriole densities were 658190/mm2 and 3011/mm2 in the
hESC-EC group, respectively, whereas those in the medium group were 392118/mm2 and 168/mm2, respectively
(P0.01). Reverse-transcription polymerase chain reaction with human-specific primers revealed mRNA expression of
human endothelial markers and human angiogenic factors in ischemic mouse tissues. The transplanted hESC-ECs were
localized as capillaries near muscle tissues in ischemic regions or incorporated into the vessels between muscle tissues, as
confirmed by human nuclear antigen staining with platelet/endothelial cell adhesion molecule or von Willebrand factor.
This study demonstrates that hESC-EC transplantation improves blood perfusion and limb salvage by facilitating postnatal
neovascularization in a mouse model of hindlimb ischemia. Thus, hESC-ECs might be useful as an alternative cell source
for angiogenic therapy.
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